4.8 Article

The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-β signaling by inactivating the TGF-β type II receptor

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.0503137102

Keywords

chromosomal translocation; congenital fibrosarcoma; TGF-beta receptor

Funding

  1. Intramural NIH HHS Funding Source: Medline
  2. NCI NIH HHS [U01 CA088199, Z01 BC005617-17, U01 CA88199] Funding Source: Medline

Ask authors/readers for more resources

An emerging theme in cancer biology is that although some malignancies occur through the sequential acquisition of different genetic alterations, certain dominantly acting oncoproteins such as those associated with chromosomal translocations have multiple functions and do not require additional mutations for cell transformation. The ETV6-NTRK3 (EN) chimeric tyrosine kinase, a potent oncoprotein expressed in tumors derived from multiple cell lineages, functions as a constitutively active protein tyrosine kinase. Here, we show that EN suppresses TGF-beta signaling by directly binding to the type II TGF-beta receptor, thereby preventing it from interacting with the type ITGF-13 receptor. This activity requires a functional EN protein tyrosine kinase, and type 11 TGF-beta receptor appears to be a direct target of EN. Our findings provide evidence for a previously undescribed mechanism by which oncogenic tyrosine kinases can block TGF-beta tumor suppressor activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available